SanegeneBio

Sanegene Bio is a clinical-stage, fully integrated biotechnology company backed by a syndicate of private equity investors. We are focused on discovering and developing best-in-class genetic medicines for obesity, cardiometabolic, and autoimmune diseases using RNA interference (RNAi) technology. Founded in 2021 by industry veterans with deep RNAi expertise, SanegeneBio is headquartered in Boston, with R&D operations in both the U.S. and China. Our proprietary technology platform, LEAD™ (Ligand and Enhancer Assisted Delivery), enables tissue-specific silencing of disease-driving genes in the liver, adipose tissue, muscle, and immune cells—achieved through safe, infrequent subcutaneous dosing. Sanegene Bio is committed to advancing transformative RNAi therapies that address global unmet medical needs.